Systematic review / meta-analysis / 2020
Glucosamine sulphate (typically 1500 mg/day) improved knee osteoarthritis outcomes without increasing adverse effects compared to placebo.
An umbrella review was conducted evaluating 11 systematic reviews covering 37 RCTs with 3,949 participants, almost all receiving 1500 mg/day of glucosamine sulphate (GS). In the meta-analyses, 9 of 17 outcomes were statistically significant, showing GS was more effective than placebo. High certainty of evidence based on GRADE supported GS over placebo for improving the Lequesne Index, joint space width change, joint space width change after 3 years, joint space narrowing, and OA progression. No difference in adverse effects was identified between GS and placebo, and systematic reviews also linked GS to improved glucose profile and physical function.
- Study type
- Umbrella review of systematic reviews and meta-analyses of RCTs
- Who was studied
- 3,949 participants across 37 RCTs from 11 systematic reviews (knee OA patients)
- What was measured
- Lequesne Index, joint space width changes, joint space narrowing, OA progression, adverse effects, glucose profile, physical function
THE PAPER
Glucosamine sulphate: an umbrella review of health outcomes.
Veronese N, Demurtas J, Smith L, Reginster JY, Bruyère O, Beaudart C, Honvo G, Maggi S, on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis. Ther Adv Musculoskelet Dis, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.